MorphoSys AG (MOR) 2010年年度报告「NASDAQ」.pdf

1、Annual Report 2010Antibodies for LifeKey Figures(IFRS)MORPHOSYS GROUP(in million,if not stated otherwise)12/31/201012/31/200912/31/200812/31/200712/31/2006RESULTS Revenues87.0 81.071.662.053.0Cost of Goods Sold7.3 6.77.17.98.0R&D Expenses46.9 39.027.622.217.5S,G&A Expenses23.2 23.920.524.821.4Person

2、nel Expenses(ExcludingStock-based Compensation)29.6 26.121.518.818.1Capital Expenditure13.8 3.83.812.04.0Depreciation2.1 1.61.51.51.5Amortization of Intangible Assets4.0 3.84.83.73.4Profi t from Operations9.8 11.416.47.06.2EBITDA(Earnings Before Interest,Taxes,Depreciation and Amortization)19.218.12

3、1.913.310.3EBIT(Earnings Before Interest and Taxes)13.112.816.58.35.4Net Profi t9.2 9.013.211.56.0BALANCE SHEET Total Assets 212.6206.1203.3184.7127.8Cash,Cash Equivalents and Available-for-sale Financial Assets108.4 135.1137.9106.966.0Intangible Assets69.2 17.419.722.314.8Total Liabilities26.6 32.2

4、41.339.227.8Stockholders Equity 185.9 173.9162.0145.5100.1Equity Ratio(in%)87%84%80%79%78%THE MORPHOSYS SHARE Number of Shares Issued 22,890,252 22,660,55722,478,78722,160,25920,145,966Earnings per Share,Diluted(in)0.40 0.400.590.530.31Dividend(in)Share Price(in)18.5317.0418.7516.1018.12PERSONNEL DA

5、TA Total Group Employees(Number)464404334295279Germany(Number)370 301236192183Other Countries(Number)941039810396BHQ880,NovartisNovartisCNTO 888,Centocor Ortho Biotech CNTO 888,Centocor Ortho Biotech Gantenerumab,RocheCNTO 1959,Centocor Ortho BiotechCNTO 3157,Centocor Ortho Biotech Centocor Ortho Bi

6、otech BAY79-4620,Bayer ScheringNovartisNovartisNovartisBoehringer IngelheimPfi zerOMP-59R5,OncoMed20 Partnered Programs30 Partnered ProgramsMOR103MOR208MOR202Early-stage Cancer ProgramsEarly-stage Anti-infl ammatory ProgramsMorphoSys/NovartisDiscoveryPreclinicPhase 1Phase 2Phase 3Market65 Partnered